Modern original drug
of natural origin from 4 species
of small marine fish
Original complex drug for the treatment of osteoarthritis of various localizations and back pain for all age groups (from 18 years)
Various drug forms.
Has a favorable safety profile,
can be used with concomitant therapy drugs
Various drug forms
2 ml
1 ml
2 ml
Alflutop®
-
More than 25 years
clinical experience
with the drug -
90% of patients
are compliant to therapy
with Alflutop®
About the brand
Alflutop®
the #1 brand
in the SYSADOA group
-
Unique studies on the efficacy of the drug 2021-2024 have been conducted
-
Included in the guidelines for LONG‑COVID infection in 2022
An important practical advantage of Alflutop® should be considered the absence of influence on hemocoagulation parameters and reduction in the need for NSAIDs, which reduces the risk of thrombotic complications characteristic of Long-COVID.
read more -
Recommended at the first stage of therapy in accordance with the Algorithms of diagnostics and treatment of osteoarthritis in 2022.
The drug Alflutop® is characterized by early analgesic effect in the 2nd week of therapy, increasing effect during 3 months and the period of after-effect up to 4-6 months.
-
Recommended in therapy in accordance with the Algorithms for diagnosis and treatment of musculoskeletal (non-specific) low back pain in 2022.
Alflutop® is widely used in osteoarthritis, at the same time a number of clinical studies confirm the efficacy of the drug also in nonspecific dorsopathy
Evidence base
Indications for use
-
Osteoarthritis of various localization
pathological condition, in which the joints are affected. The disease is manifested by inflammation, impaired mobility and deformation of the affected joint.
-
Osteochondrosis
degenerative-dystrophic disease of the spine.
-
Spondylosis
is a form of dystrophic lesion of the spine. The disease is manifested by ossification under the anterior longitudinal ligament, the specificity of which is that the resulting bony bracket wraps around the intervertebral disc. Ossification begins at the point where the anterior longitudinal ligament tears away from the vertebral body.
Features of Alflutop
-
Reduces the number
of chronic pain exacerbations and the need for NSAIDsInhibits hyaluronidase by 83%,
stimulates hyaluronic acid synthesis by 63% -
Reduces pain
in 1-2 weeks of use -
Effect builds up over
1 to 3 months after
completion of treatmentReduces extracellular release of:
IL-6 by 24% and IL-8 by 45% -
Prevents progression of osteoarthritis
Composition
The multicomponent composition determines the clinical action
-
Chondroitin-4-sulfate and Chondroitin-6-sulfate
Support cartilage hydration, improve phosphorus-calcium metabolism in cartilage tissue, accelerate its repair processes, inhibit degeneration of cartilage and connective tissue.
-
Dermatan-sulfate
Modulates the activity of growth factors.
-
Keratan-sulfate
Provides elasticity and rigidity of cartilage tissue.
-
Amino acids and peptides
Participate in protein and collagen synthesis.
-
Na+, K+, Ca+, Mg+, Fe+, Cu+, Zn ions
Influence the direction of enzyme action and activity.
Evidence base
Alflutop® is a drug with an extensive evidence base
More than 50 clinical trials involving more than 26,500 patients
- with osteoarthritis of the knee joints
- after rehabilitation
from surgery and trauma - with osteoarthritis
of the joints of the hands - with osteoarthritis of the elbow
and temporomandibular joints - with back pain
- with osteoarthritis of the hip joints
Clinical practice
Medical gymnastics
The complex of exercises was developed by the staff of the V.A. Nasonova Research Institute of Rheumatology
